论文部分内容阅读
目的 :观察阿司匹林 (ASA)和噻氯匹定 (TIC)合用对ICVD患者血小板聚集功能的影响。方法 :用花生四烯酸 (AA)、二磷酸腺苷 (ADP)、肾上腺素 (EPN)和胶原 (COL)做诱导剂检测ICVD患者合用ASA +TIC组与单用TIC或ASA组的血小板聚集率。结果 :合用组对EPN、COL、AA诱导聚集的抑制与TIC组比较差异有显著性 ,对ADP诱导聚集的抑制与ASA组比较差异有显著性 ,P均 <0 0 1。结论 :两者合用后的抗聚效果有相加及协同作用。对需加强抗聚的患者 ,在监测下小剂量的ASA和TIC合用有较好的价 /效比 ,可做为高危ICVD二级预防的一种选择。
Objective: To observe the effect of aspirin (ASA) and ticlopidine (TIC) on platelet aggregation in patients with ICVD. Methods: The platelet aggregation of ICVD patients with ASA + TIC group and TIC alone group or ASA group was detected by arachidonic acid (AA), adenosine diphosphate (ADP), epinephrine (EPN) and collagen (COL) rate. Results: The inhibition of EPN, COL, AA inducing aggregation in combination group was significantly different from that in TIC group. The inhibition of ADP induced aggregation was significantly different from that of ASA group (P <0.01). Conclusion: The combination of the two anti-poly effects have additive and synergistic effect. For patients who need to be more resistant to agglomeration, the combination of low-dose ASA with TIC has a better valence-to-effective ratio and may be an option for secondary prevention of high-risk ICVD.